Analyst firms · Leerink Partners · VRTX
Leerink Partners VRTX price target and rating history
Vertex Pharmaceuticals Incorporated (VRTX) · Health Care
Leerink Partners rates Vertex Pharmaceuticals Incorporated (VRTX) Outperform with a $594 price target, as of its latest action on Sep 21, 2026. It has published 7 rating actions on VRTX since July 2021, including 2 upgrades and 2 downgrades. Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50. Leerink Partners's $594 is 3% above that.
- Current rating
- Outperform
- Price target
- $594
- Median target, all firms
- $577.50
- Actions on VRTX
- 7
Leerink Partners price target on VRTX
Every Leerink Partners rating on VRTX
- Sep 21, 2026
- Sep 25, 2025
- May 6, 2025
- Jan 17, 2023
- May 23, 2022
- Jul 30, 2021
- Jul 20, 2021
How other firms rate VRTX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Outperform | $594 | Sep 21, 2026 |
| Morgan Stanley | Overweight | $665 | Sep 2, 2026 |
| Truist Securities | Buy | $542 | May 27, 2026 |
| Maxim Group | Buy | $575 | Mar 18, 2026 |
| Jefferies | Buy | $580 | Mar 10, 2026 |
| Oppenheimer | Outperform | $600 | Mar 10, 2026 |
| Barclays | Overweight | $606 | Jan 28, 2026 |
| RBC Capital Markets | Outperform | $546 | Jan 22, 2026 |
| Bernstein | Outperform | Jan 12, 2026 | |
| UBS | Buy | $535 | Jan 7, 2026 |
| Wolfe Research | Outperform | $548 | Jan 6, 2026 |
Questions about Leerink Partners and VRTX
- What is Leerink Partners's price target for VRTX?
- Leerink Partners's latest stated price target for Vertex Pharmaceuticals Incorporated (VRTX) is $594, from its action on Sep 21, 2026.
- What is Leerink Partners's rating on VRTX?
- Leerink Partners rates VRTX Outperform, a bullish rating, as of Sep 21, 2026.
- When did Leerink Partners last change its view on VRTX?
- On Sep 21, 2026, Leerink Partners starts coverage at Outperform, price target $594.
- How does Leerink Partners's VRTX target compare with other analysts?
- Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50. Leerink Partners's $594 is 3% above that.
More VRTX rating histories
- Morgan Stanley6
- Maxim Group3
- Jefferies3
- Oppenheimer3
- RBC Capital Markets7
- Bernstein3
- Wolfe Research5
- Raymond James3
- Wells Fargo3
- Canaccord Genuity4
- Piper Sandler3
All Leerink Partners ratingsVRTX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.